AVA-001 is under clinical development by Avalon GloboCare and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVA-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVA-001 is under development for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin’s lymphoma (NHL). The therapy constitutes of genetically manipulated autologous T cells which express a chimeric antigen receptor targeting cells expressing B lymphocyte antigen CD19 (CD-19).
Avalon GloboCare overview
Avalon GloboCare (AVCO) provides healthcare management and biotechnology development services through its core platforms. It also provides strategic advisory and outsourcing services. The company is headquartered in Freehold, New Jersy, the US.
For a complete picture of AVA-001’s drug-specific PTSR and LoA scores, buy the report here.